Table 1.
Combination indices calculated for imatinib and doxorubicin co-incubations in breast cancer cell lines
| MDA MB 231 | ||||||
|---|---|---|---|---|---|---|
| Drug | Combination Index Values at | Dm (nM) | m | r | ||
| ED 50 | ED 75 | ED 90 | ||||
| Combination (1:6000) | 1.11214 | 1.01224 | 0.99765 | 0.39732 | 1.84658 | 0.96979 |
| Doxorubicin | N/A | N/A | N/A | 0.57999 | 1.15437 | 0.97662 |
| Imatinib | N/A | N/A | N/A | 5581.5821 | 2.92342 | 0.99784 |
| MCF 7 | ||||||
| Drug | Combination Index Values at | Dm (nM) | m | r | ||
| ED 50 | ED 75 | ED 90 | ||||
| Combination (1:1200) | 1.32605 | 1.10981 | 0.95853 | 2.03607 | 1.48647 | 0.99769 |
| Doxorubicin | N/A | N/A | N/A | 4.56443 | 1.58527 | 0.96108 |
| Imatinib | N/A | N/A | N/A | 7487.20892 | 1.04304 | 0.98481 |
ED 50 (effect dosis 50%), Dm (IC50) calculated, m (measures of sigmoidicity), r (correlation coefficient)